Diabetes medication pharmacology
Open Access
- 22 February 2017
- journal article
- research article
- Published by Elsevier in BJA Education
- Vol. 17 (6) , 198-207
Abstract
Key pointsPeople with Type1 Diabetes must always have a constant source of exogenous insulin, otherwise diabetic ketoacidosis (DKA) will result.People with TypeKeywords
This publication has 15 references indexed in Scilit:
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015
- Future prospect of insulin inhalation for diabetic patients: The case of Afrezza versus ExuberaJournal of Controlled Release, 2015
- Peri‐operative management of the surgical patient with diabetes 2015Anaesthesia, 2015
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 InhibitionDiabetes Care, 2015
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care, 2014
- Risk of Lactic Acidosis or Elevated Lactate Concentrations in Metformin Users With Renal Impairment: A Population-Based Cohort StudyDiabetes Care, 2014
- Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?Diabetes, Obesity and Metabolism, 2013
- State of the art paper The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitusArchives of Medical Science, 2013
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their durationDiabetologia, 2007